Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$19.52M$19.52M+263.5% vs Q3 2022 Net Income-$10.75M-$10.75MN/M vs Q3 2022 EPS Diluted-$8.70-$8.70no prior Q3 2022 on file Operating Income-$11,807,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,792,000N/M Margins · derivedOperating margin-60.5%+166.1 pt vs Q3 2022
Net margin-55.1%+126.2 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end